PDF(Pubmed)
Abstract：
UNASSIGNED: Although the effectiveness of pentoxifylline (PF) as a selective inhibitor of phosphodiesterase to enhance sperm motility through increasing cyclic nucleotide in cases of absolute asthenozoospermia has been demonstrated for ICSI, data related to babies born from the PF-ICSI are still severely lacking. Concerns have been raised regarding the potential embryotoxicity of PF due to the controversial results obtained from the analysis of this compound on animal embryo development. This study aimed to determine whether the application of PF to trigger frozen-thawed TESA (testicular sperm aspiration) spermatozoa increases the risk of adverse obstetric and neonatal outcomes compared with non-PF frozen-thawed TESA ICSI and conventional ICSI using fresh ejaculation.
UNASSIGNED: A total of 5438 patients were analyzed in this study, including 240 patients underwent PF-TESA ICSI (ICSI using PF triggered frozen-thawed testicular spermatozoa), 101 patients underwent non-PF TESA ICSI (ICSI using frozen-thawed testicular spermatozoa) and 5097 patients underwent conventional ICSI using fresh ejaculation. Propensity score matching was executed to control the various characteristics of patients.
UNASSIGNED: No significant differences in pregnancy outcomes were observed among the three groups (PF-TESA ICSI, non-PF TESA ICSI and conventional ICSI), including biochemical pregnancy, clinical pregnancy, implantation, miscarriage, ectopic pregnancy, multiple pregnancy, and live birth, following propensity score matching. Additionally, neonatal outcomes were found to be similar among the three groups, with no statistical differences observed in the birth defect, birth weight, gestational age, preterm birth, and early-neonatal death.
UNASSIGNED: PF-ICSI may be an alternative treatment in patients using frozen-thawed testicular spermatozoa, resulting in comparable pregnancy and neonatal outcomes.
UNASSIGNED: A total of 5438 patients were analyzed in this study, including 240 patients underwent PF-TESA ICSI (ICSI using PF triggered frozen-thawed testicular spermatozoa), 101 patients underwent non-PF TESA ICSI (ICSI using frozen-thawed testicular spermatozoa) and 5097 patients underwent conventional ICSI using fresh ejaculation. Propensity score matching was executed to control the various characteristics of patients.
UNASSIGNED: No significant differences in pregnancy outcomes were observed among the three groups (PF-TESA ICSI, non-PF TESA ICSI and conventional ICSI), including biochemical pregnancy, clinical pregnancy, implantation, miscarriage, ectopic pregnancy, multiple pregnancy, and live birth, following propensity score matching. Additionally, neonatal outcomes were found to be similar among the three groups, with no statistical differences observed in the birth defect, birth weight, gestational age, preterm birth, and early-neonatal death.
UNASSIGNED: PF-ICSI may be an alternative treatment in patients using frozen-thawed testicular spermatozoa, resulting in comparable pregnancy and neonatal outcomes.
摘要：
■尽管在ICSI中已经证明了己酮可可碱（PF）作为磷酸二酯酶的选择性抑制剂通过增加环核苷酸来增强精子活力的有效性，与PF-ICSI出生的婴儿相关的数据仍然严重缺乏。由于从该化合物对动物胚胎发育的分析中获得的有争议的结果，人们对PF的潜在胚胎毒性提出了担忧。本研究旨在确定与使用新鲜射精的非PF冻融TESAICSI和常规ICSI相比，应用PF触发冻融TESA（睾丸精子抽吸）精子是否会增加不良产科和新生儿结局的风险。
■本研究共分析了5438例患者，包括240例接受PF-TESAICSI（ICSI使用PF触发的冻融睾丸精子），101例患者接受了非PFTESAICSI（使用冻融睾丸精子的ICSI），5097例患者接受了使用新鲜射精的常规ICSI。进行倾向评分匹配以控制患者的各种特征。
■三组间妊娠结局无显著差异(PF-TESAICSI,非PFTESAICSI和常规ICSI)，包括生化妊娠,临床妊娠,植入,流产,异位妊娠,多胎妊娠,和活产，遵循倾向得分匹配。此外,三组的新生儿结局相似，在出生缺陷方面没有观察到统计学差异，出生体重,胎龄,早产,和新生儿早期死亡。
■PF-ICSI可能是使用冻融睾丸精子的患者的替代治疗方法，导致具有可比性的妊娠和新生儿结局。
■本研究共分析了5438例患者，包括240例接受PF-TESAICSI（ICSI使用PF触发的冻融睾丸精子），101例患者接受了非PFTESAICSI（使用冻融睾丸精子的ICSI），5097例患者接受了使用新鲜射精的常规ICSI。进行倾向评分匹配以控制患者的各种特征。
■三组间妊娠结局无显著差异(PF-TESAICSI,非PFTESAICSI和常规ICSI)，包括生化妊娠,临床妊娠,植入,流产,异位妊娠,多胎妊娠,和活产，遵循倾向得分匹配。此外,三组的新生儿结局相似，在出生缺陷方面没有观察到统计学差异，出生体重,胎龄,早产,和新生儿早期死亡。
■PF-ICSI可能是使用冻融睾丸精子的患者的替代治疗方法，导致具有可比性的妊娠和新生儿结局。
